Disease · MONDO_0002715

uterine cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. uterine cancer. Diseases, record MONDO_0002715. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002715

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: uterine cancer; Open Targets
Open Targets ID: MONDO_0002715; Open Targets
Other names: cancer of the uterus, cancer of uterus, malignant neoplasm of the uterus, malignant neoplasm of uterus, malignant tumor of the uterus, malignant tumor of uterus, malignant tumour of the uterus, malignant tumour of uterus, malignant uterine neoplasm, malignant uterine tumor, malignant uterine tumour, malignant uterus neoplasm, uterus cancer; Open Targets
Disease Ontology: DOID:363; Disease Ontology
MeSH: D014594; MeSH
NCI Thesaurus: C3552; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 32 of its 52 drugs, from ClinicalTrials.gov; Open Targets

Drugs52

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	8	8	8	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
OLAPARIB	CHEMBL521686	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE HYDROCHLORIDE	CHEMBL1637	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
MODAFINIL	CHEMBL1373	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ASCORBIC ACID	CHEMBL196	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 52

See all 52 drugs

Targets122

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 122

See all 122 targets

Trials35

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04579380	Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations	Phase 2	217	2024-11-13	Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms	FULVESTRANT, TRASTUZUMAB, TUCATINIB	Its record names the disease	ClinicalTrials.gov
NCT00238121	Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer	Phase 2	56	2014-06-10	Recurrent Uterine Sarcoma, Stage III Uterine Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma	SORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT03241745	A Study of Nivolumab in Selected Uterine Cancer Patients	Phase 2	35	2024-12-27	Uterine Cancer, Endometrial Carcinoma, Carcinosarcoma, Leiomyosarcoma, Undifferentiated Sarcoma, High Grade Endometrial Stromal Sarcoma, Clear Cell Carcinoma	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00075400	Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer	Phase 2	26	2015-05-22	Recurrent Uterine Sarcoma, Uterine Carcinosarcoma	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT03073525	A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers	Phase 2	25	2023-04-05	Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer	ATEZOLIZUMAB, MODAFINIL	Its record names the disease	ClinicalTrials.gov
NCT00582205	Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma	Phase 2	21	2017-05-18	Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer	CISPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01367301	Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer	Not applicable	14	2023-08-21	Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Carcinosarcoma	CARBOPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03345784	Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers	Phase 1	10	2023-06-06	Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Stage I Uterine Corpus Cancer AJCC v7, Stage I Vaginal Cancer AJCC v6 and v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Vaginal Carcinoma	ADAVOSERTIB	Its record names the disease	ClinicalTrials.gov
NCT03564340	Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers	Phase 1/2	890		Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer	CEMIPLIMAB, UBAMATAMAB	Its record names the disease	ClinicalTrials.gov
NCT04590326	A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab	Phase 1/2	612		Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer	CEMIPLIMAB, FIANLIMAB, UBAMATAMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 35

See all 35 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Carcinoma vs Carcinosarcoma: Objective Overall Response Rate	2 of 37	0 of 14	51	NCT00238121	Trial comparisons
Treatment (Radiation Therapy, AZD1775 3 Days/Week, Cisplatin) Dose Level 1 vs Treatment (Radiation Therapy, AZD1775 2 Days/Week, Cisplatin) Dose Level -1: deaths from any cause	0 of 4	0 of 5	9	NCT03345784	Trial comparisons
Treatment (Radiation Therapy, AZD1775 3 Days/Week, Cisplatin) Dose Level 1 vs Treatment (Radiation Therapy, AZD1775 2 Days/Week, Cisplatin) Dose Level -1: serious adverse events	1 of 4	1 of 5	9	NCT03345784	Trial comparisons

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38471508	RESULT	1	PubMed
33753870	RESULT	1	PubMed
19307014	RESULT	1	PubMed
41777164	DERIVED	1	PubMed
39825152	DERIVED	1	PubMed
39652449	DERIVED	1	PubMed
39227583	DERIVED	1	PubMed
38653864	DERIVED	1	PubMed
37989482	DERIVED	1	PubMed
37751561	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002715

GET https://conductscience.org/api/diseases/v1/MONDO_0002715/drugs?page=2

API reference For AI assistants